Buserelin Tablet

Parastata carcinoma is a common male malignant tumor, especially more common in older men. Parastata carcinoma is usually androgen dependent, and androgens (such as testosterone) promote tumor cell proliferation and survival by binding to androgen receptors within parastata carcinoma cells. Therefore, reducing androgen levels is considered an effective method for treating parastata carcinoma.

By simulating the action of GnRH, stimulating the hypothalamic pituitary axis to secrete gonadotropins can temporarily increase testosterone levels in the initial stage. However, long-term use can cause desensitization of GnRH receptors, inhibit pituitary secretion of gonadotropins, thereby reducing testosterone secretion and ultimately lowering testosterone levels to near zero. The decrease in hormone levels is highly effective in the treatment of androgen dependent parastata carcinoma.

It is widely used in the treatment of parastata carcinoma, especially in the treatment of advanced parastata carcinoma or metastatic parastata carcinoma. Research has shown that it can effectively inhibit the secretion of androgens, thereby slowing down or preventing the growth of parastata carcinoma cells. In some clinical trials, combined use with other drugs (such as anti androgen drugs) can improve treatment efficacy, delay disease progression, and improve patient survival.

Its therapeutic effect on parastata carcinoma is significant, especially for hormone dependent parastata carcinoma patients, as it can effectively reduce androgen levels and inhibit tumor growth. However, long-term use may lead to some side effects, including hot flashes, decreased libido, and decreased bone density. Therefore, patients need to regularly monitor hormone levels and bone density during use to ensure the safety of treatment.

Mammary carcinoma is one of the most common malignant tumors in women. About 70% of mammary carcinoma is hormone dependent, especially estrogen receptor positive mammary carcinoma. Estrogen can promote the proliferation and survival of mammary carcinoma cells by binding to estrogen receptors in mammary carcinoma cells. Therefore, inhibiting estrogen level in vivo is an important strategy for the treatment of estrogen receptor positive mammary carcinoma.

By activating GnRH receptors, the hypothalamic pituitary gonadal axis is stimulated, thereby promoting the secretion of gonadotropins. When used for a long time, buserelin tablet inhibits pituitary secretion of gonadotropins through negative feedback, leading to a decrease in ovarian estrogen secretion. This hormone inhibition has therapeutic value for estrogen receptor positive mammary carcinoma.

In the treatment of mammary carcinoma, it is used as adjuvant treatment, especially in women after menopause. Research has shown that combined anti estrogen therapy (such as tamoxifen) can enhance treatment efficacy and reduce the risk of recurrence. Especially in some patients who are resistant to tamoxifen, adjuvant therapy can improve clinical outcomes.
It can also be used as a treatment method of "ovarian function depression" for mammary carcinoma patients with ovarian function recovery. By inhibiting the estrogen secretion of the ovary, it can effectively slow down the progress of mammary carcinoma, especially in the early stage of the tumor.

When used for the treatment of mammary carcinoma, it can effectively reduce the estrogen level, and then inhibit the growth of the tumor. However, similar to the side effects in the treatment of parastata carcinoma, the side effects in the treatment of mammary carcinoma may also cause hot flashes, decreased libido, decreased bone density and other side effects. Therefore, during long-term treatment, patients should undergo regular hormone level and bone density testing. 

Endometrial carcinoma is one of the most common malignant tumors in the female reproductive system, and most cases are closely related to estrogen dependence. Estrogen promotes the occurrence and development of tumors by promoting the proliferation of endometrial cells. Therefore, inhibiting the level of estrogen in the body plays an important role in the treatment of endometrial carcinoma.

By simulating the action of GnRH, it is possible to effectively inhibit the secretion of gonadotropins, thereby reducing the level of estrogen in the body. By inhibiting the synthesis of estrogen, the progression of endometrial carcinoma can be slowed down, especially in early carcinoma patients, by reducing hormone levels and preventing the proliferation and spread of tumor cells.

The application in the treatment of endometrial carcinoma is mainly reflected in inhibiting estrogen levels and slowing down the progression of carcinoma. Some studies have shown that it can be used as an adjuvant therapy for early endometrial carcinoma, especially in cases where endometrial carcinoma is hormone dependent, and its therapeutic effect is more significant.

In addition, the application of preoperative adjuvant therapy also has certain prospects, by temporarily inhibiting hormone levels, reducing tumor volume, and providing more opportunities for surgical treatment. Research also shows that when used in combination with other chemotherapy drugs, it can enhance efficacy and further improve patient survival rates.

In the treatment of endometrial carcinoma, it can significantly reduce estrogen levels and slow down tumor growth. However, long-term use of buserelin tablet may cause some side effects, such as hot flashes, decreased bone density, and decreased sexual function. Therefore, patients should receive treatment under the guidance of a doctor and undergo regular relevant examinations.